ArticleIndian pediatrics2025
FCGR2A Gene Polymorphism Association in Children with Multisystem Inflammatory Syndrome.
Article in Indian pediatrics, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Etiology Model of Kawasaki Disease and Multisystem Inflammatory Syndromes: Mast Cell Activation.Current issues in molecular biology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveFc gamma receptor IIa (FCGR2A) gene polymorphism is associated with increased susceptibility to autoimmune and infectious diseases. The aim of the present study was to evaluate the association of FCGR2A rs1801274 polymorphism with the development and severity of multisystem inflammatory syndrome in children (MIS-C).
methodsThis case-control study was conducted in a single center with MIS-C patients and healthy children. Clinical and cardiac imaging data of the participants was collected. The association between the clinical severity of the disease and FCGR2A rs1801274 polymorphism were investigated.
resultsThere was no significant association between FCGR2A rs1801274 polymorphism and cardiovascular complications in MIS-C patients. However, those with homozygous FCGR2A rs1801274 gene polymorphism developed severe cardiac dysfunction and required immunomodulatory agents other than intravenous immunoglobulin. The mean age of the patients with severe MIS-C was significantly higher than those with mild MIS-C, and systolic dysfunction was significant.
conclusionsFurther multicenter studies in different ethnic groups are needed to evaluate the association between differences in the FCGR2A rs1801274 gene and severity of MIS-C and/or other inflammatory diseases. TRIAL REGISTRY: Mersin University Clinical Trial Registry, Decision number 2022/280 dated April 20, 2022.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.